company background image
STOK logo

Stoke Therapeutics NasdaqGS:STOK Stock Report

Last Price

US$12.05

Market Cap

US$624.9m

7D

-5.6%

1Y

38.8%

Updated

20 Apr, 2024

Data

Company Financials +

Stoke Therapeutics, Inc.

NasdaqGS:STOK Stock Report

Market Cap: US$624.9m

STOK Stock Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States.

STOK fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Stoke Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Stoke Therapeutics
Historical stock prices
Current Share PriceUS$12.05
52 Week HighUS$16.40
52 Week LowUS$3.35
Beta0.76
1 Month Change101.17%
3 Month Change144.42%
1 Year Change38.82%
3 Year Change-61.84%
5 Year Changen/a
Change since IPO-52.87%

Recent News & Updates

Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist

Apr 04

Recent updates

Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist

Apr 04

Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation

Mar 21
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation

We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Dec 07
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts

May 09
Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts

Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results

May 06
Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results

Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business

May 02
Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business

We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Dec 13
We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Aug 14
Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M

Aug 08

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Apr 29
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

Jan 13
Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Sep 30
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Jun 16
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics EPS misses by $0.02

May 10

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap

Dec 14

Stoke Therapeutics prices $97.5M public offering

Nov 20

Stoke Therapeutics -2.7% AH, proposes public offering

Nov 18

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Nov 18
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics EPS in-line

Nov 12

Shareholder Returns

STOKUS BiotechsUS Market
7D-5.6%-2.5%-3.2%
1Y38.8%-3.7%19.3%

Return vs Industry: STOK exceeded the US Biotechs industry which returned -2.7% over the past year.

Return vs Market: STOK exceeded the US Market which returned 20.2% over the past year.

Price Volatility

Is STOK's price volatile compared to industry and market?
STOK volatility
STOK Average Weekly Movement24.5%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.0%

Stable Share Price: STOK's share price has been volatile over the past 3 months.

Volatility Over Time: STOK's weekly volatility has increased from 16% to 24% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014110Ed Kayewww.stoketherapeutics.com

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.

Stoke Therapeutics, Inc. Fundamentals Summary

How do Stoke Therapeutics's earnings and revenue compare to its market cap?
STOK fundamental statistics
Market capUS$624.90m
Earnings (TTM)-US$104.70m
Revenue (TTM)US$8.78m

71.2x

P/S Ratio

-6.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
STOK income statement (TTM)
RevenueUS$8.78m
Cost of RevenueUS$0
Gross ProfitUS$8.78m
Other ExpensesUS$113.48m
Earnings-US$104.70m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.02
Gross Margin100.00%
Net Profit Margin-1,192.47%
Debt/Equity Ratio0%

How did STOK perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.